LUGPA Policy Alert – CY 2027 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Final Rule
November 2026
At a Glance
CMS finalized the CY 2027 OPPS and ASC rule on November 4, 2026, introducing changes to outpatient reimbursement, surgical coverage, 340B drug payments, and hospital outpatient services.
For independent urology practices, key provisions include adding 618 codes to the ASC Covered Procedures List (CPL), removing 637 services from the Inpatient-Only (IPO) list, changing 340B drug reimbursement, and expanding prior authorization requirements for certain hospital outpatient services.
Importantly, although CMS finalized a 2.3% ASC payment update, the finalized ASC weight scalar of 0.814, compared with 0.872 in 2026, will affect procedure-level reimbursement. The impact will vary by procedure and practice case mix, and the update should not be interpreted as a uniform increase in ASC payments.
Background
The final rule updates Medicare payment policies for hospital outpatient departments and ASCs effective January 1, 2027. While CMS finalized a 2.3% update for both payment systems, the impact on individual ASCs will depend on procedure-specific payment adjustments, changes in relative weights, and case mix.
Several provisions could affect where urological procedures are performed, the economics of outpatient services, and competition between hospital-based and independent care settings.
Key Finalized Provisions
1. Expansion of the ASC Covered Procedures List
- Adds 618 codes to the ASC CPL, expanding the range of services eligible for Medicare payment in ASCs.
- Provides greater flexibility for physicians to furnish appropriate surgical services in outpatient settings.
- Urology Impact: The expansion creates potential opportunities for independent urology practices with ASC capabilities to provide additional procedures in physician-led, community-based settings. However, reimbursement and operational feasibility will vary by procedure.
2. Continued Phaseout of the Inpatient-Only List
- Removes 637 services from the Medicare IPO list for CY 2027, including procedures involving the male genital and urinary systems.
- Allows these procedures to be considered for payment in hospital outpatient settings when clinically appropriate.
- Urology Impact: The changes may expand outpatient treatment options and provide greater flexibility in determining the appropriate site of care. Removal from the IPO list does not automatically guarantee ASC coverage; applicable coverage and facility requirements still apply.
3. Changes to 340B Drug Reimbursement
- Establishes Medicare payment for 340B-acquired drugs at Average Sales Price (ASP) minus 28%, based on CMS's hospital drug acquisition cost survey.
- CMS estimates the policy will reduce Original Medicare drug payments by $4.35 billion and beneficiary drug payments by $1.1 billion in CY 2027.
- CMS estimates that beneficiaries receiving qualifying drugs in hospital outpatient departments will save an average of $900 in drug costs.
- The reduction is implemented through a budget-neutral adjustment that increases OPPS payments for non-drug services by an estimated 7.50%. This adjustment also affects ASC payment calculations through the ASC weight scaling process.
- Urology Impact: Changes to hospital drug reimbursement may affect the economics of physician-administered therapies and the financial considerations influencing where treatment is furnished. LUGPA will continue monitoring the implications for independent practices and patient access.
4. Imaging Payment Changes
- Applies Physician Fee Schedule-equivalent payment rates to specified imaging services without contrast furnished at certain grandfathered off-campus hospital outpatient departments.
- Affected services include certain X-rays, ultrasounds, CT scans, MRIs, and bone density scans. Rural Sole Community Hospitals are exempt.
- CMS estimates approximately $260 million in reduced Medicare Part B expenditures in the first year, including approximately $190 million in Medicare savings and $70 million in reduced beneficiary premiums.
- Urology Impact: The policy continues CMS's effort to address payment differences across care settings and may have implications for practices competing with hospital outpatient departments for diagnostic services.
5. Prior Authorization for Additional Botulinum Toxin Services
- Adds eight additional botulinum toxin injection codes to the hospital outpatient prior authorization program.
- Requirements apply to dates of service beginning July 1, 2027.
- CMS cites increased utilization and concerns about unnecessary services and improper payments.
- Urology Impact: Although botulinum toxin injections are used to treat urological conditions, CMS clarified that bladder Botox procedures are not included among the eight additional codes subject to prior authorization. The expansion therefore does not establish a new prior authorization requirement for bladder Botox services furnished in hospital outpatient departments.
LUGPA Perspective
LUGPA supports policies that expand access to appropriate outpatient surgical care, promote patient choice, and recognize the value of independent physician-led practices.
The addition of 618 codes to the ASC Covered Procedures List and continued phaseout of the Inpatient-Only list may create opportunities to expand access to outpatient urological care. However, expanded procedural eligibility must be accompanied by appropriate Medicare coverage and sustainable reimbursement. The 2.3% ASC payment update does not translate into a uniform increase across procedures. The finalized 0.814 ASC weight scalar, compared with 0.872 in 2026, and changes in procedure-level payment weights will produce different results depending on an individual ASC's case mix, with some procedures experiencing payment reductions.
Changes to 340B drug reimbursement also warrant close attention. Medicare payment policies should promote transparency and responsible stewardship while preserving patient access to physician-administered therapies and supporting the sustainability of independent practices.
LUGPA will continue monitoring implementation of the final rule and advocating for policies that support independent urology, patient access, and the delivery of high-quality, cost-effective care.
Additional Resources
|